Revestive 5mg (Teduglutide Vials) 5mg/0.5ml

Revestive 5mg (teduglutide) is a prescription peptide therapy supplied as 5mg/0.5ml vials for subcutaneous use. Designed to support intestinal rehabilitation, it is indicated for short bowel syndrome in adults. Store between 2–8°C and protect from light.

Strength

5mg/0.5ml

Pack Size

28s

Storage

2-8°

Manufacturer / TM Owner

Takeda Pharmaceutical Co. Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Teduglutide is used to enhance intestinal absorption in adults with short bowel syndrome who are dependent on parenteral nutrition. It works by promoting growth of the intestinal lining to improve nutrient uptake. People often ask what teduglutide is used for; this therapy targets chronic malabsorption due to surgical removal of large sections of the intestine.

Side Effects

Users may notice reduced need for parenteral nutrition over time as the gut adapts. Common effects include mild injection-site reactions and gastrointestinal changes like bloating or cramping. Some report improved stool consistency and reduced fatigue as the intestine adapts to better absorb fluids and nutrients.

Precautions & Warnings

Keep vials refrigerated at 2–8°C and use within the labeled expiry. Protect from light and avoid freezing. Use only as directed by a healthcare professional. Discard any unused portion after opening. Do not use if the solution is discolored or contains particles.

Avoid Interactions

No formal drug interaction studies have been conducted; however, teduglutide may interact with systemic corticosteroids or proton pump inhibitors. Caution is advised when combining with other gastrointestinal agents. Always inform your prescriber about all medications being taken. Avoid alcohol while using this therapy.

Frequently Asked Questions

Revestive 5mg (teduglutide) is used to treat adults with short bowel syndrome who rely on parenteral nutrition.

Teduglutide is given as a subcutaneous injection once daily, typically in the abdomen.

Common effects include injection-site reactions, bloating, cramping, and changes in stool consistency.

Revestive 5mg is a prescription-only medicine and should only be obtained through licensed pharmacies with a valid prescription.

Store vials refrigerated between 2–8°C and protect from light; do not freeze.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.